XL888

2 papers5 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funders: National Heart, Lung, and Blood Institute and 8 more

Animals2

Outcomes

p16Ink4a+ fibroblasts

downin human cells1downin mice1

1 study

XL888 decreases p16Ink4a+ fibroblasts in human cells.
“reduced p16INK4a+ fibroblasts from IPF PCLS ex vivo.”
Cellsfrom patients with idiopathic pulmonary fibrosislung
An in vivo screening platform identifies senolytic compounds that target p16INK4a+ fibroblasts in lung fibrosis
The Journal of clinical investigation7 Mar 2024
XL888 decreases p16Ink4a+ fibroblasts in mice.
“XL888 treatment eliminated pathogenic p16Ink4a+ fibroblasts in a murine model of lung fibrosis”
Animalsin a murine model of lung fibrosislung
An in vivo screening platform identifies senolytic compounds that target p16INK4a+ fibroblasts in lung fibrosis
The Journal of clinical investigation7 Mar 2024